Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hormone Antagonists

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    61 result(s) found for: Hormone Antagonists. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2016-004580-39 Sponsor Protocol Number: TOSCA_GHDDP Start Date*: 2018-07-18
    Sponsor Name:AOU FEDERICO II
    Full Title: Treatment of Growth Hormone Deficiency associated with Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Study
    Medical condition: Growth Hormone Deficiency associated with Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001292-51 Sponsor Protocol Number: CH-ACM-01-FU Start Date*: 2015-06-30
    Sponsor Name:Chiasma, Inc.
    Full Title: Follow-Up Study in Patients with Acromegaly Previously Participating in Chiasma Study CH-ACM-01
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SI (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005615-17 Sponsor Protocol Number: RPL554-008-2014 Start Date*: 2015-04-22
    Sponsor Name:Verona Pharma plc
    Full Title: A Phase II, randomised, double blind, placebo controlled, seven way crossover study to assess the effect of single doses of RPL554 compared to salbutamol and placebo administered by nebuliser on lu...
    Medical condition: Patients with chronic asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10049106 Asthma chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002814-38 Sponsor Protocol Number: SP005 Start Date*: 2013-09-27
    Sponsor Name:SOTIO a.s.
    Full Title: A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer elig...
    Medical condition: metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) BE (Completed) CZ (Completed) IT (Completed) NL (Completed) ES (Completed) HU (Completed) PT (Completed) BG (Completed) SK (Completed) PL (Completed) HR (Completed) AT (Completed) LV (Completed) LT (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-008692-33 Sponsor Protocol Number: 2008-242 Start Date*: 2009-04-21
    Sponsor Name:Department of Urology, Herlev Hospital
    Full Title: Evaluation of cytotoxicity and genetic changes of high dose vitamin C infusions in castration resistant metastatic human prostate cancer.
    Medical condition: The effect of high dose intravenous weekly vitamin c infusion in castration resistant human prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002965-39 Sponsor Protocol Number: RHMCAN0890 Start Date*: 2013-04-29
    Sponsor Name:Swiss Group for Clinical Cancer Research (SAKK)
    Full Title: Orteronel maintenance therapy in patients with metastatic castration resistant prostate cancer and non-progressive disease after first-line docetaxel therapy: A multicenter randomized double-blind ...
    Medical condition: Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004775-40 Sponsor Protocol Number: APD334-202EU Start Date*: 2021-05-11
    Sponsor Name:Arena Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Ongoing) DK (Ongoing) SK (Ongoing) LT (Ongoing) LV (Completed) HU (Ongoing) CZ (Ongoing) PT (Prematurely Ended) NO (Completed) BE (Ongoing) BG (Ongoing) ES (Ongoing) HR (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023987-41 Sponsor Protocol Number: 2010.2611 Start Date*: 2011-06-24
    Sponsor Name:University Medical Center Groningen
    Full Title: In vivo imaging of the effect of fulvestrant on availability of estrogen receptor binding sites in metastatic breast tumor lesions using [18F]FES-PET
    Medical condition: Estrogen Receptor-positive metastatic breast cancer patients that will be treated with fulvestrant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004114-99 Sponsor Protocol Number: FERTIRES-2016 Start Date*: 2017-05-18
    Sponsor Name:AB-BIOTICS
    Full Title: USE OF P.N680S POLYMORPHISM TO CHOOSE THE EXOGEN FSH DOSE IN CONTROLLED OVARIAN HYPERSTIMULATION: A PROSPECTIVE TRIAL
    Medical condition: Infertility
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003633-41 Sponsor Protocol Number: MK-3475-991 Start Date*: 2020-03-17
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate ...
    Medical condition: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) IE (Trial now transitioned) FI (Completed) GB (GB - no longer in EU/EEA) DK (Ongoing) ES (Ongoing) AT (Prematurely Ended) NL (Completed) PL (Trial now transitioned) FR (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004117-40 Sponsor Protocol Number: MK-3475-641 Start Date*: 2020-03-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) ...
    Medical condition: Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Ongoing) FR (Ongoing) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned) IT (Ongoing) CZ (Ongoing) HU (Trial now transitioned) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006114-14 Sponsor Protocol Number: 62326B1658 Start Date*: 2012-04-17
    Sponsor Name:Research and Development department
    Full Title: “Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on tr...
    Medical condition: Hypogonadism Type 2 Diabetes Cardiovascular risk
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-005251-25 Sponsor Protocol Number: CABACARE Start Date*: 2017-04-07
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, p...
    Medical condition: Metastatic Castration Resistant Prostate Cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004103-20 Sponsor Protocol Number: INO-VT-464-CL-001 Start Date*: 2011-10-13
    Sponsor Name:Innocrin Pharmaceuticals, Inc.
    Full Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects with Castration-Resistant Prostate Cancer
    Medical condition: Castration-resistant prostate cancer (CRPC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003123-57 Sponsor Protocol Number: I6T-MC-AMAC Start Date*: 2016-02-09
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitis
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) HU (Completed) NL (Completed) LT (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002234-39 Sponsor Protocol Number: BAY59-7939/15693 Start Date*: 2012-08-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY 59-7939) compared with that of dose...
    Medical condition: prevention of stroke and non-central nervous system systemic embolism in subjects with non-valvular atrial fibrillation scheduled for cardioversion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PT (Completed) ES (Completed) NL (Completed) DE (Completed) GR (Completed) BE (Completed) GB (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-002312-41 Sponsor Protocol Number: MK-3475-365 Start Date*: 2016-10-22
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Temporarily Halted) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Ongoing) SE (Trial now transitioned) DK (Trial now transitioned) IE (Trial now transitioned) IT (Ongoing) PL (Trial now transitioned) NL (Ongoing) AT (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010091-17 Sponsor Protocol Number: KIP112967 Start Date*: 2009-09-15
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from peripheral nerve injury. Estudio aleatorizado, do...
    Medical condition: Neuropathic pain
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000476-42 Sponsor Protocol Number: 20510 Start Date*: 2020-08-19
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone domi...
    Medical condition: Metastatic castration resistant prostate cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Trial now transitioned) LT (Trial now transitioned) HU (Ongoing) GB (GB - no longer in EU/EEA) FI (Trial now transitioned) AT (Trial now transitioned) DE (Ongoing) FR (Ongoing) PL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001461-32 Sponsor Protocol Number: OGX-011-12 Start Date*: 2012-07-12
    Sponsor Name:OncoGenex Technologies Inc.
    Full Title: A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant ...
    Medical condition: Metastatic Castrate Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA